John Mendlein

John D.
Mendlein was the founder of Fate Therapeutics, Inc., founded in 2007, where the title held was Vice Chairman from 2011 to 2025.
Dr. Mendlein is also the founder of Empress Therapeutics, Inc.,Sail Biomedicines Inc,Homes for Sudan..
Dr. Mendlein is Executive Chairman at Vesalius Therapeutics, Inc. starting 2025.
Dr. Mendlein is Chairman at Chimeros Therapeutics.
Dr. Mendlein is Director at Tessera Therapeutics, Inc. Dr. Mendlein is Executive Partner at Flagship Pioneering, Inc. since 2019.
Former positions include Chairman & Chief Executive Officer at Adnexus from 2005 to 2008.
Chairman, CEO & General Counsel at Affinium Pharmaceuticals Ltd. from 2000 to 2005.
Chairman & Chief Executive Officer at Laronde, Inc. in 2022.
Director & Chief Knowledge Officer at Aurora Biosciences Corp.
from 1996 to 2001.
Director at ACLARA Biosciences, Inc. from 2003 to 2004.
Director at Monogram Biosciences, Inc. from 2004 to 2009.
Independent Director at aTyr Pharma, Inc. from 2017 to 2019.
Director at Chimeros, Inc. Director at Biotechnology Innovation Organization.
Independent Director at Omega Therapeutics, Inc. from 2021 to 2024.
Director at Axcella Health, Inc. Independent Director at Editas Medicine, Inc. Director at Repertoire Immune Medicines, Inc. Director at Senda Biosciences, Inc. Director at Ohana Biosciences, Inc. Attorney at Cooley LLP.
Scientist at GlaxoSmithKline Pharmaceuticals SA (Belgium).
President-Corporate & Product Strategy at Moderna, Inc. from 2018 to 2019.
Education includes a doctorate from the University of California, Los Angeles, an undergraduate degree from the University of Miami, and a graduate degree from the University of California, Hastings.